Intarcia Therapeutics, Inc. is a biopharmaceutical company developing therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration and tolerability of drug therapies. In addition, delivering medicines just once or twice yearly virtually ensures patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins and peptides at above-body temperature and to deliver them in a constant and consistent manner via Intarcia's proprietary technology platform. Intarcia is pursuing a Phase 3-stage development program for type 2 diabetes and has additional programs ongoing for weight regulation to control obesity.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/15/12 | $210,000,000 |
Farallon Capital Management New Leaf Venture Partners The Baupost Group Venrock | undisclosed | |
| 04/01/14 | $200,000,000 |
Farallon Capital Management Foresite Capital Franklin Templeton Fred Alger Management New Leaf Venture Partners Quilvest Private Equity RA Capital The Baupost Group Venrock | undisclosed | |
| 09/15/16 | $215,000,000 |
